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INTRODUCTION
Racemic bupivacaine (RBUP) can cause life-threatening
cardiac complications, particularly when given intravascu-
larly by accident. Levobupivacaine (LBUP) was developed
as a long acting local anesthetic with a potentially reduced
toxicity compared with RBUP. LBUP is considered to be
safer than RBUP because it has a higher cardiotoxicity thresh-
old and lower risk of CVC (1). However, by the direct intra-
coronary infusions in conscious sheep, both RBUP and LBUP
caused similar fatal cardiotoxicity (2). The incidence of elec-
trical stimulation-induced ventricular tachycardia and fibrilla-
tion with LBUP was similar to that with RBUP (3). A recent
report showed that a relatively small amount of LBUP (app-
roximately 1.6 mg/kg) could lead to CVC when infused into
the systemic circulation in an anesthetized human (4). Fur-
thermore, regarding the successful resuscitation with a con-
ventional treatment, the LBUP-induced CVC failed to show
significant advantage over the RBUP-induced CVC (5, 6).
The LBUP-induced CVC may be different in the degree
of not only cardiac depression but also vascular reactivity from
the RBUP-induced CVC, as CVC is caused by cardiac depres-
sion in association with vascular collapse. In spite of less car-
diac depression, the vascular reactivity may be more compro-
mised by LBUP, thereby the resuscitation from the CVC
caused by LBUP may be as difficult as that by RBUP in some
studies (5, 6).
The resuscitation from RBUP-induced CVC with conven-
tional treatment is known to be difficult, so many modalities
have been applied for better results. Cho et al. (7) and Kim
et al. (8) proposed the feasibility of insulin for the resuscita-
tion from the RBUP-induced CVC. Considering the chan-
nel effect (9) and cardiac supportive action of insulin (10), it
can be assumed that insulin may work on the LBUP-induced
CVC.
We hypothesized that insulin may be effective in resusci-
tating the CVC by either bupivacaine, and that there may be
a different pattern of recovery between the two bupivacaines.
The possible difference in the cardiac depression and vasoac-
tivity may be augmented when insulin, which has vasodila-
tory activity in addition to positive inotropic action (11), is
used as a resuscitative agent. This study was performed to
compare the insulin-mediated recovery from the LBUP-in-
duced CVC with that from the RBUP-induced CVC, and
to assess the feasibility of insulin resuscitation for the LBUP-
induced CVC.
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The Hemodynamic Effects of Insulin Following Overdosage with 
Levobupivacaine or Racemic Bupivacaine in Dogs
Although levobupivacaine (LBUP) is less cardiotoxic than racemic bupivacaine
(RBUP), the resuscitation from the LBUP-induced cardiovascular collapse (CVC)
has not been easy as expected. Following the recent reports that proposed the
resuscitative action of insulin for the RBUP-induced CVC, a controlled trial was per-
formed to assess the feasibility of insulin for the LBUP-induced CVC. Fourteen dogs
were randomly allocated into two groups: the RBUP and LBUP groups. Each group
received continuous intravenous infusions of RBUP or LBUP until the mean arterial
pressure (MAP) reached 40 mmHg. Then, an intravenous bolus of insulin (2 U/kg)
was administered. Both groups were successfully resuscitated. At CVC, a decrease
of cardiac output and an increase of systemic vascular resistance were observed
but to a lesser degree in the LBUP group (p<0.05). After insulin injection, the MAP
further declined to under 40 mmHg for several minutes, which was more protract-
ed in the LBUP group (p<0.05). The CVCs induced by LBUP or RBUP in anes-
thetized dogs could be successfully resuscitated by insulin. Compared with RBUP,
however, the less degree of vasoconstriction by LBUP and the innate vasodilatory
property of insulin yielded a delayed increment of MAP during the immediate resus-
citation period in the LBUP-induced CVC.
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MATERIALS AND METHODS
The study was approved by the committee of animal care
and use of our institute. Enrolled were fourteen male mon-
grel dogs weighing between 19 and 32 kg. They were ran-
domly assigned to two groups (n=7 for each); the RBUP and
LBUP group. Commercial forms of RBUP (Bupivacaine HCL
Inj., Myungmun Pharmacy, Korea) and LBUP (Chirocaine
�,
Abbott Laboratories Ltd., Ireland) were used for the induc-
tion of CVC in each group.
Anesthesia was induced using thiopental sodium (10 mg/
kg) and maintained by continuous sodium pentobarbital infu-
sion (5 mg/kg/hr) and vecuronium injection (0.2 mg/kg ini-
tially and 0.02 mg/kg at 30-min intervals). The dogs were
tracheally intubated and ventilated with 100% O2 maintain-
ing normocarbia. Volume requirement during NPO time
was calculated and administered over the first half hour. Addi-
tional volume support with normal saline was initiated from
2 to 8 mL/kg in response to signs of hypovolemia during the
stabilization period. A fluid infusion of 2 mL/kg/hr was main-
tained to account for insensible losses throughout experi-
ments. Body temperature was kept at 37-38℃ and sodium
bicarbonate was administered (2-4 mEq/kg/hr) to control
the acid-base balance (pH 7.35-7.45).
Two antecubital venous catheters were used to infuse drugs
and normal saline. Both femoral arterial catheters were can-
nulated to monitor arterial pressure continuously and to col-
lect blood samples. A Swan-Ganz catheter (Opticath
�, P7110-
EH, Abbott, U.S.A.) was introduced via the external jugu-
lar vein to measure central venous pressure (CVP) and car-
diac output (CO).
After a 30-min stabilization period, RBUP or LBUP infu-
sion was started at a rate of 0.5 mg/kg/min (0.5% mixture,
both drugs) until the mean arterial pressure (MAP) reached
40 mmHg, which was defined as the time of CVC as we have
found that no dogs in two groups could survive spontaneously
at that point in our preliminary study using three dogs in
each group. At CVC, RBUP or LBUP infusion was stopped
and 2 U/kg of regular insulin (Novolin
� R, Novo Nordisk,
Denmark) was injected via a central venous catheter followed
by the infusion of D50W (2 mL/kg for 30 min) and potassium
(1-2 mM/kg/hr).
The criterion for successful resuscitation was as follows;
90% of initial MAP should be achieved by 30 min follow-
ing cardiovascular collapse and be maintained at that level for
a minimum of 30 min.
All data were collected until 60 min after CVC. MAP and
heart rate were continuously monitored and recorded at 1-
min intervals using a HP Component Monitoring SystemTM
(Hewlett-Packard Model 54S, Andover, MA). CO was record-
ed as a mean of two consecutive measurements every 5-min
throughout the experiment using the thermodilution tech-
nique. Systemic vascular resistance (SVR) was calculated using
the standard formula (SVR=80×[MAP-CVP]/CO). ECG
analysis was performed every 5-min using a resting ECG anal-
ysis system (MAC8
�, Marquette, U.S.A.). Arterial blood sam-
ples were collected to determine immediate blood gas, elec-
trolytes, and glucose levels every 10-min through the exper-
iment. Blood samples were centrifuged at 2,500 rpm for 15
min to determine total plasma drug concentrations by high
performance liquid chromatography using an ultraviolet
detector operation at a wavelength of 204 nm with a limit
of sensitivity of 4 ng/mL.
Data were expressed as mean±SD. The independent sam-
ples T-test and the Mann-Whitney U-test were used for anal-
ysis of between-group differences. Recovery phase values were
compared to the baseline values or to CVC values using the
Wilcoxon signed rank test and the Sign test with Dunnette
or Tukey post hoc testing. Time-dependent variables were
analyzed by repeated measures of ANOVA. All statistical
analyses were performed using SPSS software (Version 10.09),
and p<0.05 was considered significant.
RESULTS
There were no differences in weight, time to CVC, drug
dose required for CVC, and total plasma drug concentration
at CVC between the two groups (Table 1).
CVP increased continuously until CVC but was not differ-
ent between two groups (5±2 mmHg at baseline and 11±
2 mmHg at CVC). The infusion of bupivacaines decreased
CO continuously with the lowest value at CVC in both groups.
CO was higher in the LBUP group than in the RBUP group
at CVC (p<0.05). Calculated SVRs increased at CVC in both
groups but the SVR was significantly lower in the LBUP
Group
Weight
(kg)
N
Duration of
hypotension
<40 mmHg
(min)
Total plasma drug concentration
(mcg/mL)
CVC
End of 
experiment
Time to
CVC (min)
Dose
Total (mg)
Per weight
(mg/kg)
RBUP 7 22.4±7.7 48.6±13.5 3.4±0.5 573.4±341.3 24.3±6.7 19.2±4.5 3.1±1.3
LBUP 7 24.0±3.7 49.4±12.7 6.1±1.2* 580.9±104.6 24.6±6.6 24.7±5.0 3.5±0.7
Table 1. Comparison of basic values between two groups
Values are shown as mean±SD. CVC, cardiovascular collapse (MAP=40 mmHg); RBUP, racemic bupivacaine; LBUP, levobupivacaine.
*p<0.00, significantly longer than the RBUP group.344 C.-W. Jung, J.-T. Kim, K.-H. Lee
group than in the RBUP group (p<0.05) (Fig. 1).
After insulin injection, all dogs in both groups were suc-
cessfully resuscitated with restored baseline blood pressures,
but time spent under 40 mmHg during resuscitation was
significantly longer in the LBUP group (p<0.05). MAP dec-
lined further in both groups for minutes and then restored
40 mmHg at 3.4±0.5 min after CVC in the RBUP group
and at 6.1±1.2 min in the LBUP group (Table 1). The CO
declined in the RBUP group in excess of that observed in
the LBUP group, and the CO remained lower in the RBUP
group at each measured time interval. The SVR was higher
in the RBUP group from CVC for a period of 20 min, and
then both groups recovered the baseline SVR 40 min after
insulin injection (Fig. 1).
In addition to arrhythmias, which manifested as sinus arr-
hythmia or 1st degree AV block in the LBUP group and pre-
mature ventricular complex or a supraventricular beat in the
RBUP group immediately prior to CVC, infusion of bupi-
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Fig. 1. Sequential changes of SVR, MAP, and CO. The decrease
of CO and the increase in SVR were observed but to a lesser degree
in the LBUP group. MAP further declined to under 40 mmHg for
several minutes after insulin injection in both groups, and the res-
toration of MAP was more delayed in the LBUP group (p<0.05).
Values are expressed as mean (dots) with SD (error bars). ‘C+’
means minutes after CVC.
CVC, cardiovascular collapse (MAP=40 mmHg); RBUP, racemic
bupivacaine; LBUP, levobupivacaine; SVR, systemic vascular
resistance; MAP, mean arterial pressure; CO, cardiac output.
*p<0.05 vs. baseline value; 
� p<0.05 vs. CVC value; 
� p< 0.05 higher
than in the other group.
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Fig. 2. Sequential changes of ECG parameters such as QTc, PR,
and QRS intervals. No distinguishable changes are discovered by
ECG analysis, except PR and QRS interval prolongations at CVC.
The restoration of parametric value is only seen in QRS interval.
Values are expressed as mean (dots) with SD (error bars). ‘C+’
means minutes after CVC.
CVC, cardiovascular collapse (MAP=40 mmHg); RBUP, racemic
bupivacaine; LBUP, levobupivacaine; QTc, corrected QT.
*p<0.05 vs. baseline value; 
� p<0.05 vs. CVC value; 
� p<0.05 higher
than in the other group.
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vacaines produced prolongations of PR and QRS intervals,
which were less in the LBUP group. The restoration of ECG
parametric values during recovery was only seen in the QRS
interval in both groups (Fig. 2).
Blood sample analyses, which included acid-base balance
(pH 7.35-7.41), plasma potassium (3.7-4.4 mM), and blood
glucose (99-108 mg/dL), were within physiologic ranges thro-
ughout the experiment, and between-group differences were
not observed. Total plasma bupivacaine concentrations showed
no difference between the two groups throughout the experi-
ment. These concentrations reduced abruptly after insulin
injection (at 5 min after insulin injection, 12.2±1.6 mcg/
mL in the LBUP group, and 7.9±1.2 mcg/mL in the RBUP
group) and continued to decrease until the end of the exper-
iment.
DISCUSSION
Management of local anesthetic-induced CVC is aimed at
correcting contractile dysfunction of the heart and arrhyth-
mia. When some confounding factors such as hypoxia, hyper-
carbia, acidemia, and hyperkalemia were present, there were
increased incidences of arrhythmia with RBUP (12, 13). How-
ever, we could not determine the effect of arrhythmia on CVC
in this study because arrhythmia and ECG parametric changes
induced by two bupivacaines did not progress towards hemo-
dynamic instability when eliminating confounding factors
mentioned above. Liu et al. noticed that ‘pump failure’ was
the cause of death in the RBUP-treated anesthetized dogs
(14). We speculate that the primary cause of CVCs induced
by two bupivacaines may be hypotension from diminished
contractilities rather than arrhythmias in anesthetized dogs.
Most studies evaluating resuscitative modalities were per-
formed using RBUP, whereas only a few studies used LBUP
because LBUP has been considered safer than RBUP. There
is indirect evidence from binding kinetics to suggest that
recovery from cardiotoxicity is faster with LBUP than with
RBUP in the guinea-pig heart (15). Moreover, following the
intravenous infusion of LBUP or RBUP in conscious sheeps,
arrhythmias due to LBUP returned to sinus rhythm more
readily than those due to RBUP (16). However, the paramet-
ric changes of ECG were not outstandingly different from
each other, and the CVC induced by LBUP was as profound
as that by RBUP in our study. The potential advantage of
LBUP over RBUP was not observed in a recent study by Gro-
ban et al. in anesthetized dogs (5). After infusion of local anes-
thetics to the point of CVC, hypotension and arrhythmias
were treated with epinephrine, open-chest massage, and ad-
vanced cardiac life support protocol, respectively. They con-
cluded that, after RBUP or LBUP infusion, resuscitation is
not always successful and co-administration of epinephrine
may lead to severe ventricular arrhythmias. The CVC by LBUP
seems to require an intensive treatment such as like the CVC
caused by RBUP.
Animal studies have shown that resuscitation using sym-
pathomimetics, particularly norepinephrine and epinephrine,
improves outcome in RBUP-induced asystole (17). Howev-
er, epinephrine may exacerbate arrhythmias associated with
local anesthetic overdose without improving CO (18). Phos-
phodiesterase inhibitors having both positive inotropic and
vasodilatory actions are expected to improve CO. However,
they do not necessarily support blood pressure, and are asso-
ciated with a significant incidence of ventricular arrhythmias
(19).
Cho et al. reported that, after the infusion of RBUP in dogs,
treatment with a combination of insulin and glucose facili-
tated recovery of blood pressure, cardiac output, and ECG
parameters (7). They supposed that intracellular K
+ transport
by insulin counteracts RBUP inhibition of transient outward
current improving rates of myocardial repolarization. They
also proposed that insulin might have an effect on calcium
homeostasis and sodium channel dynamics, and that cate-
cholamine release might account for the benefit of insulin
resuscitation. Weinberg and VadeBoncouer proposed the ener-
gy-related mechanism of insulin during resuscitation stating
that insulin’s cardiac supportive effect is due to promoted use
of fatty acid as a metabolic source by the ischemic heart (20).
We postulated that insulin might show such a favorable result
in resuscitation from the LBUP-induced CVC as in the RB-
UP-induced CVC, if the same mechanism worked when the
heart remained in a state of extreme depression.
Insulin seems to be effective for the resuscitation from the
LBUP-induced CVC but with substantial delays. In dogs,
increases in plasma insulin levels to high physiological con-
centrations did not increase blood pressure because increases
in cardiac output were offset by decreases in vascular resistance
(21). Similarly, in humans, short-term insulin infusion failed
to increase arterial pressure possibly by the same mechanism
(22). In this study, the vasodilatory effect was also seen fol-
lowing administration of insulin, but a discrepancy existed
between two groups; in spite of higher cardiac output, the
restoration of MAP in the LBUP group was more protract-
ed than that in the RBUP group. We infer that LBUP is less
cardiac depressive than RBUP, but vascular reactivity to com-
pensate the cardiac depression may be more compromised
in the presence of LBUP. The unfavorable results from pre-
vious reports on the resuscitation from the LBUP-induced
CVC might have been due to the fact that LBUP has a rela-
tively more vasodilatory property than RBUP and the vasoac-
tivity plays a role in the CVC induced by LBUP. In this study,
the discrepancy in immediate restoration of blood pressure
seems to be due to the difference in vascular reactivity between
the two bupivacaines, which was combined by the systemic
vasodilatory effect of a large bolus of insulin.
Shaffner et al. demonstrated the importance of early institu-
tion of cardiopulmonary resuscitation because a delay beyond
6 min markedly impairs the ability to generate viable levels346 C.-W. Jung, J.-T. Kim, K.-H. Lee
of cerebral blood flow in dogs (23). Furthermore, even at cere-
bral perfusion pressure of 35 mmHg after 6 mins of CVC,
cerebral metabolic recovery is incomplete and inadequate to
restore full reperfusion. The perfusion pressure and time, less
than 40 mmHg for 6 min during the early resuscitation period
in the LBUP group, is comparable with their results, empha-
sizing the risk of recovery lag.
Insulin may be a good choice in managing the RBUP-in-
duced CVC because the severely depressed heart generally
responds negatively to increased afterload and insulin may
facilitate the recovery by lowering the afterload. However,
based on our findings, the management strategy of the LBUP-
induced CVC may differ from that of the RBUP-induced
CVC. Insulin can be effectively used for treating the LBUP-
induced CVC, but insulin or any inotropes with a vasodila-
tory activity may need adjunctive therapy to abolish the hy-
potensive recovery lag during the immediate resuscitation
period because of lowered SVR.
In conclusion, a single injection of insulin can resuscitate
CVCs induced by LBUP or RBUP in anesthetized dogs, but
the innate vasodilatory property of insulin in combination
with the less increased SVR delays the restoration of blood
pressure during the immediate resuscitation period in the
LBUP-induced CVC.
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